Perspective Therapeutics (NYSE:CATX) Earns “Outperform” Rating from Wedbush

Wedbush restated their outperform rating on shares of Perspective Therapeutics (NYSE:CATX) in a report issued on Friday,RTT News reports. Wedbush currently has a $11.00 price target on the stock.

CATX has been the topic of several other research reports. Royal Bank of Canada restated an “outperform” rating and set a $16.00 price target on shares of Perspective Therapeutics in a research note on Tuesday, January 14th. Bank of America downgraded shares of Perspective Therapeutics from a “buy” rating to a “neutral” rating and cut their target price for the company from $24.00 to $5.00 in a research report on Monday, November 25th. UBS Group initiated coverage on shares of Perspective Therapeutics in a research report on Thursday, October 24th. They issued a “buy” rating and a $20.00 price target for the company. Finally, Oppenheimer dropped their price objective on shares of Perspective Therapeutics from $22.00 to $16.00 and set an “outperform” rating on the stock in a research note on Friday, November 22nd. One investment analyst has rated the stock with a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $15.14.

Perspective Therapeutics Price Performance

Perspective Therapeutics stock opened at $4.01 on Friday. The firm has a 50-day moving average of $3.68 and a two-hundred day moving average of $9.76. Perspective Therapeutics has a 1 year low of $2.70 and a 1 year high of $19.05.

Perspective Therapeutics (NYSE:CATX) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.21) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.21). The firm had revenue of $0.37 million during the quarter. Perspective Therapeutics had a negative return on equity of 27.40% and a negative net margin of 4,096.66%. Equities analysts forecast that Perspective Therapeutics will post -0.88 EPS for the current fiscal year.

Insiders Place Their Bets

In other Perspective Therapeutics news, CEO Johan M. Spoor purchased 8,000 shares of the company’s stock in a transaction dated Wednesday, December 4th. The shares were acquired at an average price of $3.77 per share, for a total transaction of $30,160.00. Following the completion of the purchase, the chief executive officer now owns 36,257 shares of the company’s stock, valued at approximately $136,688.89. The trade was a 28.31 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Jonathan Robert Hunt acquired 12,829 shares of the firm’s stock in a transaction that occurred on Monday, November 25th. The stock was bought at an average cost of $3.82 per share, with a total value of $49,006.78. Following the completion of the transaction, the chief financial officer now directly owns 48,800 shares in the company, valued at $186,416. The trade was a 35.66 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last three months, insiders have bought 67,570 shares of company stock valued at $256,789. 3.52% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Perspective Therapeutics

A number of large investors have recently made changes to their positions in the stock. nVerses Capital LLC purchased a new position in Perspective Therapeutics in the 3rd quarter worth $57,000. Trueblood Wealth Management LLC raised its stake in shares of Perspective Therapeutics by 37.0% in the fourth quarter. Trueblood Wealth Management LLC now owns 22,236 shares of the company’s stock worth $71,000 after purchasing an additional 6,000 shares during the last quarter. Koa Wealth Management LLC acquired a new stake in shares of Perspective Therapeutics during the fourth quarter worth about $83,000. SG Americas Securities LLC boosted its position in Perspective Therapeutics by 41.3% in the fourth quarter. SG Americas Securities LLC now owns 26,088 shares of the company’s stock valued at $83,000 after buying an additional 7,627 shares during the last quarter. Finally, US Bancorp DE increased its holdings in Perspective Therapeutics by 142.7% in the 3rd quarter. US Bancorp DE now owns 6,576 shares of the company’s stock worth $88,000 after buying an additional 3,866 shares during the period. 54.66% of the stock is owned by hedge funds and other institutional investors.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.